Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line

A Rapid and Sensitive Method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding

1976 • 225,752 citations

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

1976 • 200,127 citations

New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening

1990 • 9,412 citations

Plant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata^1,2

1966 • 2,159 citations

DNA TOPOISOMERASES

1985 • 1,524 citations

Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin.

1989 • 1,030 citations

Clinical Pharmacology of 5-Fluorouracil

1989 • 910 citations

Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11.

1991 • 855 citations

DNA Topoisomerase I—Targeted Chemotherapy of Human Colon Cancer in Xenografts

1989 • 645 citations

On the mechanism of topoisomerase I inhibition by camptothecin: evidence for binding to an enzyme-DNA complex

1989 • 533 citations

Synthesis of water-soluble (aminoalkyl)camptothecin analogs: inhibition of topoisomerase I and antitumor activity

1991 • 513 citations

Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy.

1997 • 434 citations

Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.

1996 • 360 citations

Irinotecan is an active agent in untreated patients with metastatic colorectal cancer.

1996 • 340 citations

Fluorouracil in colorectal cancer--a tale of two drugs: implications for biochemical modulation.

1997 • 340 citations

Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies.

1972 • 315 citations

Comparison of Topoisomerase I Inhibition, DNA Damage, and Cytotoxicity of Camptothecin Derivatives Presently in Clinical Trials

1994 • 291 citations

Heterogeneous DNA damage and repair in the mammalian genome.

1987 • 274 citations

Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer.

1972 • 271 citations

Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880).

1970 • 246 citations

Effects of CPT‐11 in combination with other anti‐cancer agents in culture

1992 • 226 citations

Drosophila DNA topoisomerase I is associated with transcriptionally active regions of the genome.

1984 • 225 citations

Camptothecin, a specific inhibitor of type I DNA topoisomerase, induces DNA breakage at replication forks.

1988 • 214 citations

The involvement of active DNA synthesis in camptothecin-induced G2 arrest: altered regulation of p34cdc2/cyclin B.

1992 • 209 citations

Effects of Uracil Incorporation, DNA Mismatches, and Abasic Sites on Cleavage and Religation Activities of Mammalian Topoisomerase I

1997 • 199 citations

A model for tumor cell killing by topoisomerase poisons.

1990 • 172 citations

Cytotoxic Effects of Topotecan Combined With Various Anticancer Agents in Human Cancer Cell Lines

1996 • 171 citations

Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors.

1996 • 149 citations

Differential Stabilization of Eukaryotic DNA Topoisomerase I Cleavable Complexes by Camptothecin Derivatives

1995 • 121 citations

Reversed-phase high-performance liquid chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasma

1994 • 110 citations

CPT-11 (Irinotecan) in the treatment of colorectal cancer

1995 • 104 citations

Posttreatment exposure to camptothecin enhances the lethal effects of x-rays on radioresistant human malignant melanoma cells

1992 • 97 citations

Time-schedule dependency of the inhibiting activity of various anticancer drugs in the clonogenic assay

1985 • 93 citations

Sequence-dependent activity of the irinotecan-5FU combination in human colon-cancer model HT-29 in vitro and in vivo.

1997 • 88 citations

Mammalian DNA topoisomerase I mediates the enhancement of radiation cytotoxicity by camptothecin derivatives.

1997 • 78 citations

Simultaneous determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in cancer patients

1992 • 76 citations

Studies on the role of topoisomerases in general, gene- and strand-specific DNA repair

1993 • 64 citations

DNA topoisomerases and DNA repair

1988 • 60 citations

Clinical trials with the topoisomerase I inhibitors.

1992 • 60 citations

CPT-11 (Irinotecan) and 5-Fluorouracil: a Promising Combination for Therapy of Colorectal Cancer

1996 • 42 citations

Cell surface alterations associated with exposure of leukemia L1210 cells to fluorouracil.

1980 • 36 citations

Aberrant cell cycle inhibition pattern in human colon carcinoma cell lines after exposure to 5-fluorouracil

1995 • 34 citations

Therapeutic efficacy of fluoropyrimidines depends on the duration of thymidylate synthase inhibition in the murine colon 26-B carcinoma tumor model.

1996 • 32 citations

Do antimetabolites interfere with the glycosylation of cellular glycoconjugates?

1990 • 26 citations

9th Nci-Eortc Symposium on New Drugs in Cancer Therapy

1995 • 25 citations

Interleukin-1 alpha-induced modulation of topoisomerase I activity and DNA damage: implications in the mechanisms of synergy with camptothecins in vitro and in vivo.

1996 • 7 citations